Two School of Medicine faculty receive NHGRI 2020 Genomic Innovator Awards
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has selected two Duke University School of Medicine faculty to receive 2020 Genomic Innovator Awards. NHGRI honored a total of 12 early career investigators in genomics. Each awardee will receive five years of funding.
RCA Recap! How to Budget and Manage Grant Finances
The following are links shared during the August RCA! How to Budget and Manage Grant Finances, presented by Deborah Martin. To view this session (or other RCA! Professional Development sessions) please visit the OPSD Resources page, and choose the Research Careers Ahead! tab.
Anxious and depressed? Experts share tips for coping in a pandemic
Four Duke experts offered advice on getting back some control.
Meet the team powering Duke's COVID-19 surveillance testing efforts
This large-scale pooled testing effort was designed and coordinated by dozens of Duke’s faculty, researchers and staff across disciplines.
Keeping a close watch on COVID-19 with surveillance tests
Duke’s effort to track COVID-19’s presence in the campus community opens up a new front as the university begins an ambitious, semester-long surveillance testing program.
REKAPP Program
If applying to the Duke CTSA KL2, please consider the REACH Equity and KL2 Application Preparation Program (REKAPP). 
Duke Clinical Research Update
SUPPORT OFFICE HOURS
REDCap Office Hours
Email redcap-docr@duke.edu to schedule a virtual session at one of the times indicated below.
Tuesdays 10 AM, virtual sessions
Wednesdays 10 AM, virtual sessions
Thursdays 2 PM, virtual sessions
Fridays 10 AM, virtual sessions
SlicerDicer Office Hours
Thursdays, 1 PM, via WebEx
Duke Clinical Research Update August 19 2020
Research Community News
iRIS/OnCore Updates
DOCR News
Recruitment Innovation Corner
Did You Know?
Training Opportunities
Clinical Research Employee Highlights
Duke institute tapped to test monoclonal antibody preventative for COVID-19
The Duke Human Vaccine Institute Pandemic Prevention Program (DHVI-P3) has received an additional $7.6 million in federal funding to manufacture and test in humans a neutralizing monoclonal antibody for the prevention of COVID-19.